Canadians affected by the use of the prescription drug Rexulti could cash in on a $4.75 million class-action lawsuit settlement.

On Aug. 23, Toronto-based law firm Rochon Genova shared a public notice announcing that both parties had reached an agreement on the proposed settlement. The settlement is still pending approval from the Superior Court of Québec.

The issue

A class action lawsuit against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. was authorized on Dec. 3, 2021.

“The Class Action alleges that Rexulti can cause, contribute, or exacerbate a variety of compulsive behaviours and impulse control disorders, specifically compulsive or pathological gambling, hypersexuality, binge-eating, and uncontrollable shopping,” reads the court document .

The lawsuit claims

See Full Page